Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia

Current Oncology

Volumn 20, Issue 3, 2013, Pages

  Altwairgi, A K ^a,b   Hopman, W M ^a   Mates, M ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

Adjuvant chemotherapy; Early stage breast cancer; Febrile neutropenia; Filgrastim; Pegfilgrastim; Practice patterns; Primary prophylaxis with granulocyte colony stimulating factors

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIMARY PREVENTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION;

EID: 84878747573     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1306     Document Type: Article

References (41)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society; 2011.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-717.
3. Ginés J, Sabater E, Martorell C, Grau M, Monroy M, Casado MA. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol 2011;13:485-98.
4. Aapro MS, Cameron DA, Pettengell R, et al. On behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (GCSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53.
5. Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2003;23:15S-9S.
6. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66.
7. Aapro M, Schwenkglenks M, Lyman GH, et al. Pegfilgrastim primary prophylaxis VS. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010;74:203-10.
8. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-31.
9. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
10. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Ver. 1.2010. Fort Washington, PA: NCCN; 2010.
12. Aapro MS, Bohlius J, Cameron DA, et al. ON behalf of the European Organisation for Research and Treatment of Cancer. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32.
13. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHUG-CSF): the first 10 years. Blood 1996;88:1907-29.
14. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage ii or stage iii/iv breast cancer. J Clin Oncol 2002;20:727-31.
15. Green MD, Koelbl H, Baselga J, et al. on behalf of the International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase iii study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
16. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
17. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
18. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84.
19. Soong D, Haj R, Leung MG, et al. High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol 2009;27:e101-2.
20. Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006;14:901-9.
21. Takabatake D, Taira N, Hara F, et al. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol 2009;39:478-83.
22. Madarnas Y, Dent SF, Husain SF, et al. Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres. Curr Oncol 2011;18:119-25.
23. Gerlier L, Lamotte M, Awada A, et al. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. BMC Cancer 2010;10:642-52.
24. Younis T, Rayson D, Thompson K. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer 2012;20:2523-30.
25. Vandenberg T, Younus J, Al-Khayyat S. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol 2010;17:2-3.
26. Campbell C, Bramwell V, Charette M, Oliver T on behalf of the Systemic Treatment Disease Site Group. The Role of Colony-Stimulating Factor (CSF) in Patients Receiving Myelosuppressive Chemotherapy for the Treatment of Cancer. Practice guideline report 12-2. Toronto, ON: Cancer Care Ontario; 2003.
27. Fraser J, Steele N, Al Zaman A, Yule A. Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with fe100c-d chemotherapy in a nontribal population of node positive breast cancer patients compared with pacs-01 trial group. Eur J Cancer 2011;47:215-20.
28. Martin M, Pienkowski T, Mackey J, et al. On behalf of the Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
29. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for nodepositive breast cancer patients: the fnclcc pacs 01 Trial. J Clin Oncol 2006;4:5664-71.
30. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-37.
31. Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:1917-27.
32. Crawford J, Caserta C, Roila F On behalf of the ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 2010;21(suppl 5):v248-51.
33. Ng JH, Ang XY, Tan SH, Tao M, Lim ST, Chan A. Breakthrough febrile neutropenia and associated complications in non-Hodgkin's lymphoma patients receiving pegfilgrastim. Acta Haematol 2011;125:107-14.
34. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M on behalf of the OPPS Working Group and ANC Study Group. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving chop chemotherapy. Leuk Lymphoma 2003;44:2069-76.
35. Timmer-Bonte JN, Punt CJ, vd Heijden HF, et al. Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung Cancer 2008;60:222-30.
36. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade iv neutropenia and bone pain: a metaanalysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-95.
37. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9.
38. Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009;31:1092-104.
39. Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 2011;27:79-86.
40. Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007;27:1387-93.
41. Alemayehu D, Cappelleri JC. Revisiting issues, drawbacks and opportunities with observational studies in comparative effectiveness research. J Eval Clin Pract 2011;:[Epub ahead of print].